141 results about "Inflammatory cell" patented technology

The invention belongs to the technical field of bioengineering, and particularly relates to leuconostoc mesenteroides subsp. Mesenteroides FTCM002 and application thereof in preparation of dendrobium officinale leavening with the effects of reducing blood sugar, nourishing the stomach and resisting inflammation. Dendrobium officinale is subjected to enzymolysis and inoculated with the strain for fermentation, and the obtained fermented dendrobium officinale has the effect of inhibiting alpha-glucosidase; the gastric mucosal injury can be relieved, the expression of VEGF, IL-6, IL-8 and TNF-alpha in the gastric mucosal injury is reduced, and the effect of nourishing the stomach is achieved; the cell phagocytic rate can be increased, the NO concentration and the content of immune factors IL-6 and TNF-alpha can be increased, and the effect of enhancing the immunity is achieved; the expression quantity of IL-6, IL-1beta and TNF-alpha in inflammatory cells can be reduced, and the anti-inflammatory effect is achieved.

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.

The invention relates to the technical field of pharmaceutical preparations, and provides double-shell JAK inhibitor nanoparticles, a preparation method thereof and targeted delivery eye drops. The double-shell JAK inhibitor nanoparticle provided by the invention comprises a core, an inner shell and an outer shell, wherein the core comprises a nanostructure lipid carrier and a JAK inhibitor; the inner shell layer is a cationic polymer, and the outer shell layer is hyaluronic acid. Through the design of the positive charge inner shell layer and the negative charge outer shell layer, the dual functions of mucosa adhesion and active targeting are achieved, the surface of the nanoparticle is electronegative finally, cytotoxicity possibly caused by direct exposure of a cationic polymer is reduced, non-specific aggregation of the cationic polymer and electronegative protein in tears is avoided, and the stability of tears is improved. And the stability of the preparation is improved. The eye drops provided by the invention can obviously prolong the residence time of the JAK inhibitor on the ocular surface, enhance the cornea permeability, can actively target to ocular inflammatory cells, and have a wide application prospect.

The invention discloses a quantitative index determination method and device based on a hepatitis pathology image, equipment, a medium and a product, and relates to the field of medical pathology image artificial intelligence analysis, and the method comprises the steps: obtaining an image of a liver puncture pathology section; according to the image of the hepatic puncture pathological section, performing feature extraction by using a multi-stage model cascade architecture to obtain a pathological feature result; the multi-stage model cascade architecture comprises an improved VM-UNet segmentation model and a VM classification model based on FEM enhancement, and the VM classification model is connected with the improved VM-UNet segmentation model; the pathological feature result comprises the expansion level of the manifold area, the necrosis type of the manifold area and the inflammatory cell information of the manifold area; and calculating a quantitative index according to the pathological feature result. According to the invention, the accuracy, objectivity, consistency and repeatability of identification can be improved.

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

The invention relates to application of hydroxynidone to preparation of a medicine for preventing and / or treating radiation-induced pulmonary fibrosis. Pharmacological experiments prove that the hydroxynidone has a definite resisting effect on radioactive rat lung injury including early inflammatory exudation and pulmonary interstitial fibroblast hyperplasia, and can obviously reduce pulmonary alveolar inflammatory cell exudation and reduce the content of TGF beta 1 in inflammatory exudate; the medium and large doses have the effect of delaying the development of interstitial pneumonia towards pulmonary fibrosis; the lesion degrees of the small, medium and large dosage groups are obviously reduced and are in a dose-effect relationship.

The invention relates to application of roxburgh rose-derived exosomes (RrNVs) in preparation of products for preventing, improving or treating acute lung injury (ALI). Specifically, the rosa roxburghii tratt exosome (RrNVs) can effectively inhibit inflammation, improve the acute lung injury symptom, reduce the release of inflammatory cells and inflammatory mediators in the acute lung injury state, and relieve the pulmonary edema condition, the lung tissue leakage condition and the lung capillary permeability condition in the inflammatory state. Meanwhile, the RrNVs can also regulate and control the intestinal flora structure, improve the abundance of beneficial bacteria and reduce the abundance of harmful bacteria, and the discovery provides a basis for the RrNVs as potential functional food, medicine and the like of ALI.

A skin care composition includes a plurality of agents that include at least one retinol derivative that may comprise, for example, hydroxypinacolone retinoate, and at least one bark extract that may comprise, for example, Eperua falcata bark extract, the plurality of agents providing reduced retinol associated inflammation as compared with a composition that includes the at least one retinol and lacks the at least one bark extract. The plurality of agents may also include hydroxy acid, for example, comprising lactic acid. The composition may confer one or a combination of increased skin cell proliferation, improved cellular migration, improved cellular differentiation, an anti-inflammatory retinol genetic signature as demonstrated by via bulk-RNA sequencing of human keratinocytes and restores epidermal disruption and reduce IL-1A and IL-23 inflammatory cytokines in human ex-vivo skin models of chronic inflammation.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a marine small molecule peptide and an active variant thereof in preparation of a medicine for treating skin diseases, the marine small molecule peptide and the active variant thereof can effectively inhibit keratinocyte pan apoptosis induced by TNF-alpha and IFN-gamma, the formation of a PANoptosome complex is blocked through a multi-target synergistic effect, and the effect of treating the skin diseases is achieved. The oxidative stress is reduced, and mitochondria is stabilized, so that a skin inflammatory cell death network is inhibited from the source. The variant has the same high sequence as the peptide, retains the activity of inhibiting cell pan-apoptosis, and has enhanced stability, skin permeability, in vivo half-life or efficacy. Based on the action mechanism, the peptide and the variant thereof can be used for preparing medicines for preventing and treating intractable skin diseases such as epidermis necrolysis, psoriasis, atopic dermatitis, skin lupus erythematosus and lichen planus. The invention also provides a composition containing the peptide or the variant thereof, and dosage forms comprise an external preparation and an injection.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

The invention discloses an application of thermal sensitive Sibestein granules in treating / or preventing asthma, and belongs to the technical field of biological medicines. The invention finds that the thermal sensitive Sibestein granules can reduce the total number of cells and the number of eosinophilic granulocytes, neutrophil granulocytes and lymphocytes in asthma mice BALF, reduce the level of cell factors in asthma mice BALF and IgE in serum, reduce exudation of inflammatory substances in airway and alveolar tissues of asthma mice and infiltration of inflammatory cells, improve the lesion degree of lung tissues, and improve the curative effect of the lung tissues. The action mechanism may be related to regulation and control of MAPK / NF-kappa B signal channel related protein expression, so that inflammatory response and cell apoptosis are inhibited, and airway inflammation of mice is relieved.

The invention belongs to the technical field of medicines, and particularly relates to application of muscone in preparation of a medicine for preventing or treating aortic dissection and the medicine. The invention relates to application of muscone in preparation of a medicine for preventing or treating aortic dissection. The medicine comprises one or more of the following effects: inhibiting aortic dilatation and dissection; aortic dilatation and dissection rupture are inhibited; the infiltration of macrophages in the aorta is inhibited; the apoptosis of aortic smooth muscle cells is inhibited; the effect of reducing inflammatory cytokines in the aorta is achieved; retrogressive lesions of the aortic medial membrane are inhibited; the degradation of the aortic dissection extracellular matrix is inhibited.

The three-dimensional propaganda and education model comprises a model main body, an identification assembly and a supporting base, the model main body is made of a transparent material, and an unqualified sputum specimen simulation unit (such as saliva and a polluted sputum specimen) and a qualified sputum specimen simulation unit (such as white viscous sputum, yellow viscous sputum and bloody sputum) are arranged in the model main body; each unit is of an independent cavity structure, and the sputum character is visually displayed by accurately controlling the color and viscosity and simulating particles (such as squamous epithelial cells or inflammatory cells); the identification assembly is used for clearly marking the type and the qualified standard through an identification board and a fluorescent coating; the supporting base provides stable placement. Through materialized comparison, the patient can quickly distinguish the sputum type, so that the retention quality is improved from the source, the percent of pass is remarkably improved, the nursing load is reduced, and the method has the advantages of intuition, standardization, high efficiency, safety and the like.

[Problem]The present invention demonstrates that, when added to the culture, DHMBA inhibits the proliferation of mouse inflammatory macrophage RAW264.7 cells, promotes their cell death, and reduces their cell number. It also demonstrates that DHMBA suppresses the increased production of inflammatory cytokines in RAW264.7 cells cultured with LPS, and in particular, DHMBA treatment suppresses osteoclast formation in RAW264.7 cells stimulated with LPS. Thus, the present invention provides a useful means of treating inflammatory diseases using DHMBA.[Solution]The present invention is characterized by having an anti-inflammatory effect by including 3,5-dihydroxy-4-methoxy benzyl alcohol (DHMBA) as an active ingredient.

Disclosed are a myocarditis-targeted radionuclide molecular probe, a preparation method therefor, and an application thereof. The myocarditis-targeted radionuclide molecular probe includes a DPP4 inhibitor, a bifunctional chelator covalently bonded to an amino group of the DPP4 inhibitor, and a metallic radionuclide coordinately bonded to the bifunctional chelator. The myocarditis-targeted radionuclide molecular probe provided by the present disclosure exhibits high specificity and good targeting capability, and demonstrates significant uptake in myocardial inflammatory cells, and low uptake in non-target tissues. Characterized by high resolution and sensitivity of imaging, the myocarditis-targeted radionuclide molecular probe is applied for early diagnosis of cardiac inflammatory infiltration severity, therapeutic efficacy evaluation, prognosis assessment and the like, and has promising clinical and application prospects in the field of non-invasive nuclear medicine diagnosis and treatment as a myocarditis imaging agent.

The application discloses a kind of pentapeptide-based supramolecular assembly particles and its application as drug delivery carrier, belong to the field of biological assembly material.The TGCP of the present application, TGCP / nHA are prepared from TP5, HA and GA into carrier particles with drug loading performance and potential anti-inflammatory performance, it has spontaneous fluorescence performance, and can exist stably in neutral and alkaline environment, can be decomposed in acidic environment, can be loaded with small molecules with different solubility, and has certain programmed response performance at physiological and pathological pH.The present application is found through in-vitro experiment exploration that the carrier particles have good biocompatibility, and for in-vitro induced inflammatory cell experiment, it is found that TGCP and TGCP / nHA both have certain anti-inflammatory activity, can inhibit the expression of cell inflammatory factor IL-6, and play the role of inhibiting inflammation.

This invention discloses a biomimetic nanocomposite, its preparation method, and its application in the preparation of products for treating atherosclerosis, belonging to the field of pharmaceutical preparation technology. The biomimetic nanocomposite is an Ir-TiO2 metal nanozyme encapsulated in an M2 macrophage membrane. This invention prepares a structurally biomimetic nanocomposite by coating Ir-TiO2 nanoparticles with an M2 macrophage membrane. After intravenous injection, the formed biomimetic nanocomposite actively targets endothelial cells in atherosclerotic lesions, releasing Ir-TiO2 antagonistically into the cytoplasm of plaque-containing endothelial cells and inflammatory macrophages. Once Ir-TiO2 reaches the lesion site, it exerts an enzymatic effect to achieve anti-inflammatory activity and promotes cholesterol excretion from inflammatory cells such as macrophages and smooth muscle cells at the lesion site, reducing intracellular lipid deposition, reducing foam cell formation, and promoting plaque growth. This nanotherapy can effectively prevent the progression of inflammation in atherosclerotic lesions and alleviate atherosclerosis.

Compositions comprising at least one nanoparticle containing a nucleoside RNA molecule encoding FOXP3 and an optional second agent are described herein. In some cases, the RNA molecule is circular and contains one or more IRES. Methods for treating or preventing inflammation are also described herein.

The application discloses a kind of self-assembly nanomaterial and its application in ROS clearance.The self-assembly nanomaterial of the application is denoted as TPP-FFYp-O, and its structural formula is shown as follows:TPP-FFYp-O of the application is specifically cut to generate TPP-FFY-O by alkaline phosphatase (ALP) overexpressed after entering inflammatory cell, TPP-FFY-O is enriched near mitochondrion by the targeting effect of TPP, and is self-assembled to form nanoparticle and stays in inflammatory cell by π-π stacking.Nanoparticle surface enrichment of a large number of TEMPO can convert superoxide radical anion (O2 ·‑ ) in mitochondrion into hydrogen peroxide (H2O2), and then decompose into oxygen and water, thereby significantly reducing the ROS level in inflammatory cell.This enzyme-controlled self-assembly nanoparticle improves the stability of TEMPO and the ability of ROS clearance, and has good application prospect.

A method for preparing cells for therapeutic use is provided, comprising culturing a population of progenitor cells under cell culture conditions that promote progenitor cell differentiation, including the presence of G-CSF, GM-CSF, IL-3, and TNF, to generate a population of granulocyte-producing cells. The generated granulocyte-producing cells may be useful in therapeutic methods, including the treatment of cancer and infections, and may also be useful in modulating inflammatory cell responses.

The invention discloses a preparation method of a coronary artery microcirculation disturbance animal model, and belongs to the technical field of biological medicine. According to the method, the stable mouse CMD model can be established by injecting 20-40 [mu] g / mL Calcimycin into the cardiac apex for the first time. Calcimycin is a calcium ion (Ca < 2 + >) carrier commonly used in a laboratory and can transport calcium ions outside cells into the cells, so that the concentration of the calcium ions in the cells is increased. Particularly, when 40 [mu] g / mL of Calcimycin is injected, the pathological severity of the Calcimycin is further aggravated, myocardial fiber arrangement is disordered, boundary is unclear, a large number of myocardial cells are necrotic and dissolved, cavitation is formed, vascular wall degeneration swelling is caused, inflammatory cell infiltration is caused, and thrombus is formed in microvessels.

The application discloses a polymer microneedle patch co-loaded with self-antigen peptides and immunomodulators and a preparation method thereof, and studies the ability of the polymer microneedle patch to reverse immune dysfunction of rheumatoid arthritis (RA). The preparation method is as follows: a biocompatible polymer matrix material and a self-antigen are dissolved in pure water, and then an immunomodulator is added to obtain a suspension by stirring. The suspension is added to a mold to form needle tips, a backing layer solution is poured after drying, and finally the microneedle patch is demolded. Animal experiments show that the microneedle has sufficient mechanical strength to deliver drugs transdermally, effectively induces tolerogenic dendritic cells at the drug delivery site, further activates the differentiation of regulatory T cells (Treg), significantly up-regulates anti-inflammatory cytokines, down-regulates pro-inflammatory cells, antibodies and cytokines, effectively restores the immune balance of rheumatoid arthritis, and finally almost completely eliminates the symptoms and inflammatory infiltrates of rheumatoid arthritis. The microneedle preparation method is simple and rapid, and has a good clinical transformation prospect.

The invention discloses application of irisin in treatment of acute lung injury / acute respiratory distress syndrome. The research finds that the plasma irisin level is obviously reduced in ARDS patients, and the survival prognosis of the patients with the lower irisin level is poorer. Neutrophil as the most inflammatory cells is a cause for promoting lung tissue injury. Further analysis finds that the level of irisin is in negative correlation with the number of circulating neutrophils, and irisin incubation can significantly reduce in-vitro survival promoting (apoptosis delay) phenotypes of neutrophils in ARDS mouse alveolar lavage fluid. Iris receptor integrin alphaVbeta5 inhibitor treatment can promote neutrophil infiltration and aggravate an ARDS process. The invention provides a novel therapeutic drug and strategy for the treatment of acute lung injury / acute respiratory distress syndrome.

This invention belongs to the field of biomedical technology, specifically relating to the application of SMOC2 protein in the preparation of psoriasis treatment drugs. The amino acid sequence of the SMOC2 protein is shown in SEQ ID NO.1. This invention has discovered that SMOC2 protein can treat psoriasis, and therefore provides the application of SMOC2 protein in the preparation of psoriasis treatment drugs. Using SMOC2 protein can treat or improve the scaling, erythema, and thickening phenotypes of the skin, as well as inhibit the abnormal proliferation of keratinocytes and the expression of inflammatory factors IL1β, IL23, cAMP, TNFα, CXCL2, CXCL3, S100A8, and S100A9. By inhibiting the infiltration of neutrophils in inflammatory cells in psoriatic lesions, it exerts a therapeutic or alleviating effect on inflammatory skin diseases.

The application belongs to the technical field of medicine, and discloses application of a perilla leaf extract in preparation of a medicine for treating and / or preventing asthma-chronic obstructive pulmonary disease (ACO). The perilla leaf extract has a significant curative effect in treating and / or preventing ACO disease, can significantly improve aggregation of inflammatory cells in the lung of an ACO mouse and generation levels of inflammatory factors, and improve lung function and pathological changes of lung tissue inflammation; in addition, the perilla leaf extract can significantly inhibit generation of neutrophil inflammatory factors TNF-alpha, IL-6 and IL-1beta, and inhibit generation of an eosinophil inflammatory factor TNF-alpha.

The invention belongs to the field of analytical chemistry, and provides a method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry, differentiated pretreatment schemes are designed aiming at different biological matrixes such as excrement, serum, colon tissue and NCM460 inflammatory cells through a liquid chromatography-tandem mass spectrometry technology, matrix interference is effectively eliminated, and the method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry is provided. A quantitative analysis method with high sensitivity and high selectivity is established; the method is successfully applied to an ulcerative colitis (UC) rat model and a lipopolysaccharide (LPS)-induced NCM460 inflammation model, and a technical means is provided for revealing a metabolic regulation mechanism of medicine intervention on UC; the method solves the technical problem that various metabolites in a tryptophan metabolic pathway are difficult to detect in the prior art, is suitable for metabolic mechanism research, drug intervention effect evaluation and large-scale detection of clinical samples of inflammatory bowel diseases such as UC, and provides a technical basis for systematic research of a tryptophan metabolic network.

The invention provides a spanishneedles herb exosome as well as a preparation method and application thereof in acute lung injury, and belongs to the technical field of biological medicines. According to the preparation method of the spanishneedles herb exosome provided by the invention, the spanishneedles herb exosome can be extracted from a plant source through a simple method. In one embodiment of the invention, a lung injury model constructed by using LPS is used as an experimental animal to verify the therapeutic effect of the spanishneedles herb exosome. Results show that after the spanishneedles herb exosome is used for treatment, mouse lung tissue injury and inflammatory cell exudation can be relieved, and lung injury caused by LPS can be relieved; tNF-alpha and IL-1beta in lung lavage fluid of a mouse are remarkably reduced, and lung inflammation infiltration of the mouse can be relieved. Therefore, the spanishneedles herb exosome has the effect of treating the acute lung injury and can be used for preparing the medicine for treating the acute lung injury.

The application discloses a blood purification membrane for removing proinflammatory cytokines and a preparation method thereof. The method comprises the following steps: dissolving a film-forming material and an additive in a solvent to obtain a homogeneous casting solution; preparing a hollow fiber plasma separation membrane by using a non-solvent phase inversion method; and constructing a proinflammatory cytokine adsorption functional layer on the outer surface of the hollow fiber plasma separation membrane to obtain a homogeneous blood purification membrane. The blood purification membrane prepared by the method has the plasma separation function, can separate inflammatory cytokines from the inner side of the membrane to the outer side of the membrane, and has excellent blood compatibility on the inner surface of the membrane and the adsorption and removal function of pathogenic toxins and proinflammatory cytokines on the outer surface of the membrane. In the construction process, the two functions do not interfere with each other, the blood compatibility of the material is improved, the removal rate of the pathogenic toxins is not affected, and the problem of the reduction of the toxin adsorption and removal effect caused by the existing technology for improving the blood compatibility of the plasma perfusion adsorption resin is solved.

The invention discloses an actinomycete lipopeptide compound extracted from actinomycetes blue gray. The structure of the actinomycete lipopeptide compound is selected from one of the following structures. When the concentration of the actinomycetes lipopeptide compound extracted from the actinomycetes blue gray, especially the compound 5, is 20 [mu] mol / L, aggregation and migration of inflammatory cells in intestinal tracts of zebra fish can be significantly reduced, which indicates that the actinomycetes lipopeptide compound has an obvious anti-inflammatory effect. Therefore, the actinomycete lipopeptide compound can be used as a medicine for treating the inflammatory bowel disease.

The invention belongs to the technical field of biological medicine, and particularly relates to a nano-micelle preparation loaded with minocycline and application of the nano-micelle preparation to treatment of cerebral hemorrhage, the nano-micelle preparation is prepared by taking a polyethylene glycol-polycaprolactone nano material PEG3000-PCL2000 as a carrier, and jointly loading minocycline MINO and a CD147 monoclonal antibody Anti-CD147, so that the nano-micelle preparation is prepared. And the bionic nano-drug MINO (at) PNM (at) CD147 with an active targeting function is constructed. The nano-micelle preparation has a brain targeting property and can be enriched in cerebral hemorrhage tissues, so that the local drug concentration and the treatment efficiency are remarkably improved; the traditional Chinese medicine composition can improve neurological impairment caused by cerebral hemorrhage and significantly reduce the volume of cerebral hematoma, and has an obvious treatment effect on cerebral hemorrhage; the number of inflammatory cells in the peripheral area of hematoma and expression of inflammatory mediators can be remarkably reduced, and therefore the inflammatory response in cerebral hemorrhage tissue is relieved.